Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference34 articles.
1. American College of Cardiology (2020) HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. from https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 17 Mar 2020
2. Banu N, Panikar SS, Leal LR, Leal AR (2020) Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications. Life Sci 256:117905
3. Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, Roguski L, Noor K, Shek A, Gallagher K, Zakeri R, Shah A, Teo J, Dobson RJB (2020) Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-site UK acute Hospital Trust. medRxiv: 2020.2004.2007.20056788
4. Brown JD (2020) Antihypertensive drugs and risk of COVID-19? The Lancet Respir Med 8(5):e28.
5. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW (2020) Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi 48:E008
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献